Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 17/20 | 0.60 |
| ▸ | CA1 | P00915 | 16/20 | 0.60 |
| ▸ | CA2 | P00918 | 16/20 | 0.60 |
| ▸ | CA12 | O43570 | 7/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181495 | 0.86 | CA9 (0.67) | CA9CA1CA2CA12USP2 | |
| SCHEMBL13907005 | 0.85 | CA9 (0.57) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14806746 | 0.83 | CA9 (0.57) | CA9CA1CA2CA12USP2 | |
| SCHEMBL18633954 | 0.83 | CA9 (0.63) | CA9CA1CA2CA12USP2 | |
| SCHEMBL15828111 | 0.82 | CA9 (0.83) | CA9CA1CA2CA12USP2 | |
| SCHEMBL13971293 | 0.82 | USP2 (0.72) | CA9CA1CA2CA12USP2 | |
| SCHEMBL2742845 | 0.82 | CA9 (0.58) | CA9CA1CA2CA12USP2 | |
| SCHEMBL14426895 | 0.82 | USP2 (0.68) | CA9CA1CA2CA12USP2 | |
| 5-Iodoacetamidofluorescein SCHEMBL10146553 | 0.82 | CA9 (0.66) | CA9CA1CA2CA12USP2 | |
| SCHEMBL12793932 | 0.82 | CA9 (0.66) | CA9CA1CA2CA12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078671-A1 | INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130078671-A1 | INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078671-A1 | INCORPORATION OF TWO DIFFERENT NONCANONICAL AMINO ACIDS INTO A SINGLE PROTEIN | AARS1, NSUN3, NPEPPS | CA9 4786/4885CA1 4284/4885CA2 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.